To: 5.1.2e, 5.1.2e.[5.1.2e @minvws.nl]; 5.1.2e, 1.2. (5.1.2e)[5.1.2e @minvws.nl]; 5.1.2e, 5.1.2e. (5.1.2e)[5.1.2e @minvws.nl]; 5.1.2e, 5.1.2e. (5.1.2e)[5.1.2e @minvws.nl]
Cc: 5.1.2e, 1.2. (5.1.2e)[5.1.2e @minvws.nl]; 5.1.2e, 5.1.2e, 5.1.2e(5.1.2e)[5.1.2e @minvws.nl]; 5.1.2e, 5.1.2e. 5.1.2e 5.1.2e (5.1.2e)[5.1.2e @minvws.nl]; 5.1.2e, 5.1.2e. (5.1.2e)[5.1.2e @minvws.nl]; 5.1.2e, 1.2. 5.1.2e 5.1.2e (5.1.2e)[5.1.2e @minvws.nl]
From: 5.1.2e, 5.1.2e. (5.1.2e)
Sent: Fri 1/29/2021 4:48:35 PM
Subject: FW: Moderna - Update to delivery guidance
Received: Fri 1/29/2021 4:48:35 PM

Zie onderstaand.

Van: 5.1.2e 5.1.2e @modernatx.com> **Namens** 5.1.2e 5.1.2e
Verzonden: vrijdag 29 januari 2021 17:24
Aan: Minister van VWS < 5.1.2e @minvws.nl>
CC: 5.1.2e < 5.1.2e @modernatx.com>; 5.1.2e < 5.1.2e @modernatx.com>
Onderwerp: Moderna - Update to delivery guidance

Dear Minister de Jonge,

I hope this finds you well.

As your colleagues working on the vaccination rollout will shortly be made aware, if they haven't already been, Moderna is sharing revised delivery guidance.

We would like to reassure you that Moderna continues to expect to meet quarterly delivery commitments including for Q1 2021. Volumes will fluctuate during the ramp up period, in particular as we continue to build up our drug substance manufacturing. We are very pleased with the progress to date, given the complexity of vaccine manufacturing and the unprecedented speed at which the manufacturing infrastructure has been built up to support our product. We remain focused on operating at the highest level of quality to ensure the safety of the vaccine.

We recognise the importance of delivery planning for your vaccination rollout and will remain in close contact with you moving forwards.

Should you have any questions, or wish to discuss this in more detail, please do let us know.

Kind Regards,

5.1.2e 5.1.2e

5.1.2e 5.1.2e

Vice President EMEA | modernatx.com

moderna

Please consider the environment before printing this email

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.